Regeneron Pharmaceuticals Inc Could Rise a Lot According to The Today’s Call Option Activity

 Regeneron Pharmaceuticals Inc Could Rise a Lot According to The Today's Call Option Activity

In today’s session Regeneron Pharmaceuticals Inc (REGN) registered an unusually high (231) contracts volume of call trades. Someone, most probably a professional was a very active buyer of the November, 2016 call, expecting serious REGN increase. With 231 contracts traded and 8284 open interest for the Nov, 16 contract, it seems this is a quite bullish bet. The option with symbol: REGN161118C00400000 closed last at: $3.6 or 25% down. About 551,740 shares traded hands. Regeneron Pharmaceuticals Inc (NASDAQ:REGN) has declined 4.08% since March 30, 2016 and is downtrending. It has underperformed by 7.09% the S&P500.

Analysts await Regeneron Pharmaceuticals Inc (NASDAQ:REGN) to report earnings on November, 2. They expect $2.27 earnings per share, down 12.36% or $0.32 from last year’s $2.59 per share. REGN’s profit will be $231.75 million for 37.89 P/E if the $2.27 EPS becomes a reality. After $2.11 actual earnings per share reported by Regeneron Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts 7.58% EPS growth.

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Ratings Coverage

Out of 19 analysts covering Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), 9 rate it a “Buy”, 1 “Sell”, while 9 “Hold”. This means 47% are positive. Regeneron Pharmaceuticals Inc. has been the topic of 40 analyst reports since July 28, 2015 according to StockzIntelligence Inc. The stock of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) earned “Hold” rating by Zacks on Tuesday, August 11. The firm has “Buy” rating by Canaccord Genuity given on Wednesday, August 5. Leerink Swann initiated the stock with “Outperform” rating in Friday, February 5 report. The stock has “Outperform” rating given by Bernstein on Wednesday, August 5. The firm earned “Buy” rating on Thursday, August 6 by Argus Research. Wells Fargo initiated the stock with “Outperform” rating in Friday, December 4 report. The rating was maintained by Leerink Swann on Monday, August 3 with “Outperform”. The firm has “Neutral” rating given on Friday, August 5 by Robert W. Baird. Credit Suisse initiated Regeneron Pharmaceuticals Inc (NASDAQ:REGN) on Wednesday, January 20 with “Neutral” rating. The firm has “Outperform” rating by Leerink Swann given on Monday, April 4.

According to Zacks Investment Research, “Regeneron Pharmaceuticals Inc. is a biopharmaceutical company that discovers, develops, and intends to commercialize therapeutic drugs for the treatment of serious medical conditions. Regeneron’s platform technologies include Targeted GenomicsTM, FunctionomicsTM, and Designer Protein TherapeuticsTM. Regeneron has drugs in clinical and preclinical development for the potential treatment of obesity, rheumatoid arthritis, cancer, allergies, asthma, amyotrophic lateral sclerosis, constipating conditions, ischemia, and other diseases and disorders. (PRESS RELEASE)”

Insitutional Activity: The institutional sentiment increased to 1.19 in Q2 2016. Its up 0.44, from 0.75 in 2016Q1. The ratio increased, as 51 funds sold all Regeneron Pharmaceuticals Inc shares owned while 154 reduced positions. 50 funds bought stakes while 193 increased positions. They now own 70.88 million shares or 9.49% less from 78.30 million shares in 2016Q1.
Concert Wealth Mngmt accumulated 0.04% or 936 shares. Advantus Cap last reported 7,901 shares in the company. Keybank Natl Association Oh holds 1,907 shares or 0% of its portfolio. Investors last reported 0.69% of its portfolio in the stock. The Maryland-based Ithaka Grp Inc Limited Liability Company has invested 3.21% in Regeneron Pharmaceuticals Inc (NASDAQ:REGN). Glob X Management Limited Liability Corp reported 134 shares or 0% of all its holdings. Winfield Assoc reported 15 shares or 0% of all its holdings. Kcg Hldg accumulated 0.06% or 8,677 shares. Genesee Valley Trust Co has 0.68% invested in the company for 3,005 shares. Cap has invested 0.05% of its portfolio in Regeneron Pharmaceuticals Inc (NASDAQ:REGN). Enterprise Fincl Services Corporation reported 21 shares or 0% of all its holdings. Nordea Inv Mngmt Ab holds 0.03% or 33,264 shares in its portfolio. Principal Group Incorporated Incorporated last reported 0.05% of its portfolio in the stock. The New York-based Art Lc has invested 0.23% in Regeneron Pharmaceuticals Inc (NASDAQ:REGN). Guardian Life Co Of America has 0.01% invested in the company for 290 shares.

Insider Transactions: Since May 17, 2016, the stock had 1 insider buy, and 3 insider sales for $20.55 million net activity. The insider GOLDSTEIN JOSEPH L sold 2,125 shares worth $903,125. On Tuesday, May 17 Van Plew Daniel P sold $1.70M worth of the stock or 4,413 shares. Shares for $396,640 were sold by RYAN ARTHUR F. The insider Sanofi bought $23.55M.

Regeneron Pharmaceuticals, Inc. is a biopharmaceutical firm that discovers, invents, develops, makes and commercializes medicines for the treatment of serious medical conditions. The company has a market cap of $35.12 billion. The Company’s segment includes activities related to the discovery, development and commercialization of pharmaceutical products for the treatment of serious medical conditions. It has a 53.7 P/E ratio. It commercializes medicines for eye diseases, high low-density lipoprotein cholesterol and a rare inflammatory condition, and has product candidates in development in other areas of unmet medical need, including oncology, rheumatoid arthritis (RA), asthma, atopic dermatitis, pain and infectious diseases.

REGN Company Profile

Regeneron Pharmaceuticals, Inc., incorporated on January 11, 1988, is a biopharmaceutical firm that discovers, invents, develops, makes and commercializes medicines for the treatment of serious medical conditions. The Company’s segment includes activities related to the discovery, development and commercialization of pharmaceutical products for the treatment of serious medical conditions. The Firm commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol and a rare inflammatory condition, and has product candidates in development in other areas of unmet medical need, including oncology, rheumatoid arthritis (RA), asthma, atopic dermatitis, pain and infectious diseases. The Company’s marketed products include EYLEA (aflibercept) injection, Praluent (alirocumab) Injection and ARCALYST (rilonacept) injection for subcutaneous use. The Firm has over 10 product candidates in clinical development. These consist of Trap clinical programs and over 10 human monoclonal antibody product candidates. The Firm has generated each of the antibodies using its VelocImmune technology. The Company’s ARCALYST (rilonacept) Injection for subcutaneous Use is available in the United States for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Auto-inflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS), in adults and children over 12 year.

More news for Regeneron Pharmaceuticals Inc (NASDAQ:REGN) were recently published by: Fool.com, which released: “Better Buy: Regeneron Pharmaceuticals, Inc. vs. Roche Holding AG” on October 13, 2016. Fool.com‘s article titled: “Is Another Blockbuster Drug on the Way for Regeneron Pharmaceuticals, Inc.?” and published on October 10, 2016 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Related posts

Leave a Comment